Related Experiment Video
Updated: Feb 10, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
Published on: July 22, 2025
Framework conditions facilitating paediatric clinical research
Anne-Laure Knellwolf1, Stéphane Bauzon, Ornella Della Casa Alberighi
1Dept, of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy. anne.knellwolf@iss.it
Insights
Unlicensed medicines are common in children. The European Paediatric Medicines Regulation aims to improve pediatric medicine research quality while protecting children from unnecessary trials.
Area of Science:
- Pediatric pharmacology
- Medicinal law and ethics
Background:
- Widespread use of unlicensed and off-label medicines in pediatric populations.
- Children constitute approximately 25% of the European population, yet face medication risks.
- Current practices involve 50-80% of medicines lacking pediatric authorization.
Purpose of the Study:
- Analyze ethical and legal challenges posed by the European Paediatric Medicines Regulation.
- Provide recommendations for improved clinical research frameworks in pediatric medicine.
Main Methods:
- Review of the European Paediatric Medicines Regulation (effective January 26, 2007).
- Ethical and legal analysis of regulatory impacts on pediatric drug development.
- Formulation of recommendations for facilitating pediatric clinical research.
Main Results:
- The regulation seeks to enhance the quality of pediatric medicine research.
- It aims to balance research needs with the protection of children from excessive clinical trials.
- Identified ethical and legal issues require specific attention for effective implementation.
Conclusions:
- The European Paediatric Medicines Regulation is a significant step towards safer pediatric medication.
- Addressing identified ethical and legal issues is crucial for successful implementation.
- Recommendations are proposed to foster a supportive environment for pediatric clinical research.
Abstract:
The use of unlicensed and "off-label" medicines in children is widespread. Between 50-80% of the medicines currently administered to children have neither been tested nor authorized for their use in the paediatric population which represents approximately 25% of the whole European population. On 26 January 2007, entered into force the European Regulation of Paediatric Medicines. It aims at the quality of research into medicines for children but without subjecting the paediatric population to unnecessary clinical trial. This article addresses ethical and legal issues arising from the regulation and makes recommendations for the framework conditions facilitating the development of clinical research with children.
More Related Videos
Related Concept Videos
Conditions on Early Earth
Facilitated Transport
Facilitated Transport
Social Facilitation
Facilitated Diffusion
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
Classical Conditioning
Ivan Pavlov observed that dogs...

